A 62-year-old man with personal history of arterial hypertension and smoking was admitted to our hospital with ST elevation myocardial infarction. Intravenous fibrinolytic therapy was given by emergency services during hospital transfer, which was effective. Routine coronary angiography showed moderate lesion on the proximal left anterior descending, proximal coronary aneurysm (Figure 1A, aster...

Over the past decade, the advent of drug-eluting stents (DES) has revolutionised the field of interventional cardiology by having a major impact on patient care through their efficacy in reducing the need for repeat revascularisation. A number of stents capable of delivering an anti-proliferative agent designed to prevent neointimal hyperplasia, the principal mechanism of restenosis after stent...

Background—The objective was to evaluate the role of risk factors and stent type for stent thrombosis (ST) using a large real world registry. Methods and Results—We evaluated all consecutive coronary stent implantations in Sweden from May 1, 2005, to June 30, 2007. All cases of ST, documented in the Swedish coronary angiography and angioplasty registry until September 21, 2008, were analyzed. S...

Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after ...

insights from the randomized TAXUS II trial. Circulation 2005;111:900–905. 27. Wieneke H, Dirsch O, Sawitowski T, Gu YL, Brauer H, Dahmen U, Fischer A, Wnendt S, Erbel R. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Catheter Cardiovasc Interv 2003;60: 399–407. 28. Kollum M, Farb A, Schreiber R, Terfera K, Arab A, Geist A, Haberstroh ...

BACKGROUND Polymer formulation may affect the efficacy of drug-eluting stents. Resolute, Endeavor, and ZoMaxx are zotarolimus-eluting stents with different stent platforms and different polymer coatings and have been tested in clinical trials. The aim of this analysis was to compare the efficacy of zotarolimus-eluting stents with different polymers. METHODS AND RESULTS Data were obtained from...

CONTEXT Placement of sirolimus-eluting stents or paclitaxel-eluting stents has emerged as the predominant percutaneous treatment strategy in patients with coronary artery disease (CAD). Whether there are any differences in efficacy and safety between these 2 drug-eluting stents is unclear. OBJECTIVE To compare outcomes of sirolimus-eluting and paclitaxel-eluting coronary stents on the basis o...

A 65-year-old man had undergone percutaneous revascularization of the left anterior descending artery four years earlier, with two non-overlapping stents being implanted in the same procedure: a first-generation drug-eluting stent (DES) in the proximal segment (2.75 mm×16 mm TAXUS Element paclitaxel-eluting stent) and a second-generation DES in the mid segment (2.5 mm×24 mm PROMUS Element evero...

Patients with diabetes mellitus have worse outcomes after percutaneous coronary intervention than patients without diabetes mellitus. We compared the risk of stent thrombosis, myocardial infarction, death, and target lesion revascularization in diabetic and nondiabetic patients after implantation of drug-eluting stents or bare metal stents. In the Western Denmark Heart Registry, 12,347 consecut...

PURPOSE To evaluate MR safety at 3 Tesla for a drug eluting coronary stent. METHODS A drug eluting coronary stent (Endeavor, cobalt alloy, Medtronic Vascular, Santa Rosa, CA) was evaluated for magnetic field interactions, heating, and artifacts at 3 Tesla. MRI-related heating was assessed with the stent in a gelled saline-filled phantom using a transmit/received RF body coil with a whole body...